Noteworthy ACPAs have been shown to have a significant clinical impact as an independent factor in systemic bone mass loss in various cohorts of early arthritis patients, comparing bone mineral density values between ACPA-positive and ACPA-negative individuals [52,53]. The gene discussed is PRTN3; the disease is arthritic joint disease.